Loading...
Market
Will Chimagen Biosciences receive a milestone payment from GSK by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
GSK financial reports and press releases
Story
GSK Acquires Investigational Lupus Drug from Chimagen Biosciences for $850 Million
Oct 29, 2024, 12:13 PM
GSK has announced the acquisition of an investigational drug from Chinese biotech firm Chimagen Biosciences for up to $850 million. This move aims to enhance GSK's pipeline of potential treatments for lupus, addressing ongoing unmet needs in autoimmune diseases. The acquisition reflects GSK's strategy to expand its portfolio in the competitive biopharmaceutical market, particularly in the area of autoimmune disorders.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than €100 million • 33%
Between €100 million and €500 million • 33%
More than €500 million • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%